PREVENTION OF THE CONVERSION OF PHARMACEUTICAL AGENTS INTO TOXIC N-NITROSAMINE COMPOUNDS

A pharmaceutical composition, which is an oral solid dosage form, containing a pharmaceutical agent comprising a dialkylamino- or a trialkylamino-group and one or more pharmaceutically acceptable excipient(s),wherein over a period of2 weeks at 60° C. under open exposure (at any humidity between 30 a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	GUJJAR, Chaitanya Yogananda, FITZNER, Ansgar, RALLABANDI, Bala Ramesha Chary, SAGILI, Manohar Reddy, MANKALA, Santhosh Kumar, DÖBBER, Alexander, KALAMATA, Venkatasimhadri Naidu, MADALLAPALLI, Kiran Kumar
Format:	Patent
Sprache:	eng
Schlagworte:	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page
container_issue
container_start_page
container_title
container_volume
creator	GUJJAR, Chaitanya Yogananda FITZNER, Ansgar RALLABANDI, Bala Ramesha Chary SAGILI, Manohar Reddy MANKALA, Santhosh Kumar DÖBBER, Alexander KALAMATA, Venkatasimhadri Naidu MADALLAPALLI, Kiran Kumar
description	A pharmaceutical composition, which is an oral solid dosage form, containing a pharmaceutical agent comprising a dialkylamino- or a trialkylamino-group and one or more pharmaceutically acceptable excipient(s),wherein over a period of2 weeks at 60° C. under open exposure (at any humidity between 30 and 75% rH), or6 months at 40° C./75% rH in the primary packaging, or6 months at 25° C./60% rH in the primary packagingthe concentration of the corresponding N-nitroso-derivative of the pharmaceutical agent remains below 50 ppm (relative to the weight of the free base of the pharmaceutical agent in the pharmaceutical composition).
format	Patent
fullrecord	<record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_US2023056424A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>US2023056424A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_US2023056424A13</originalsourceid><addsrcrecordid>eNqNi0EKwjAQAHPxIOofFjwXalq9h5iagNkNybb0VorEk2ih_h8V-gBPA8PMWvQhms4gO0KgBtga0ISdiWkxwarolTYtO62uoC7fOIFDJmDqnQYs0HGkpLzD3-wDtXhOW7G6j4857xZuxL4xrG2Rp9eQ52m85Wd-D22SpazK46mWtTpU_1Uf5fMyiA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>PREVENTION OF THE CONVERSION OF PHARMACEUTICAL AGENTS INTO TOXIC N-NITROSAMINE COMPOUNDS</title><source>esp@cenet</source><creator>GUJJAR, Chaitanya Yogananda ; FITZNER, Ansgar ; RALLABANDI, Bala Ramesha Chary ; SAGILI, Manohar Reddy ; MANKALA, Santhosh Kumar ; DÖBBER, Alexander ; KALAMATA, Venkatasimhadri Naidu ; MADALLAPALLI, Kiran Kumar</creator><creatorcontrib>GUJJAR, Chaitanya Yogananda ; FITZNER, Ansgar ; RALLABANDI, Bala Ramesha Chary ; SAGILI, Manohar Reddy ; MANKALA, Santhosh Kumar ; DÖBBER, Alexander ; KALAMATA, Venkatasimhadri Naidu ; MADALLAPALLI, Kiran Kumar</creatorcontrib><description>A pharmaceutical composition, which is an oral solid dosage form, containing a pharmaceutical agent comprising a dialkylamino- or a trialkylamino-group and one or more pharmaceutically acceptable excipient(s),wherein over a period of2 weeks at 60° C. under open exposure (at any humidity between 30 and 75% rH), or6 months at 40° C./75% rH in the primary packaging, or6 months at 25° C./60% rH in the primary packagingthe concentration of the corresponding N-nitroso-derivative of the pharmaceutical agent remains below 50 ppm (relative to the weight of the free base of the pharmaceutical agent in the pharmaceutical composition).</description><language>eng</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2023</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230223&DB=EPODOC&CC=US&NR=2023056424A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25543,76293</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230223&DB=EPODOC&CC=US&NR=2023056424A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>GUJJAR, Chaitanya Yogananda</creatorcontrib><creatorcontrib>FITZNER, Ansgar</creatorcontrib><creatorcontrib>RALLABANDI, Bala Ramesha Chary</creatorcontrib><creatorcontrib>SAGILI, Manohar Reddy</creatorcontrib><creatorcontrib>MANKALA, Santhosh Kumar</creatorcontrib><creatorcontrib>DÖBBER, Alexander</creatorcontrib><creatorcontrib>KALAMATA, Venkatasimhadri Naidu</creatorcontrib><creatorcontrib>MADALLAPALLI, Kiran Kumar</creatorcontrib><title>PREVENTION OF THE CONVERSION OF PHARMACEUTICAL AGENTS INTO TOXIC N-NITROSAMINE COMPOUNDS</title><description>A pharmaceutical composition, which is an oral solid dosage form, containing a pharmaceutical agent comprising a dialkylamino- or a trialkylamino-group and one or more pharmaceutically acceptable excipient(s),wherein over a period of2 weeks at 60° C. under open exposure (at any humidity between 30 and 75% rH), or6 months at 40° C./75% rH in the primary packaging, or6 months at 25° C./60% rH in the primary packagingthe concentration of the corresponding N-nitroso-derivative of the pharmaceutical agent remains below 50 ppm (relative to the weight of the free base of the pharmaceutical agent in the pharmaceutical composition).</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2023</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNi0EKwjAQAHPxIOofFjwXalq9h5iagNkNybb0VorEk2ih_h8V-gBPA8PMWvQhms4gO0KgBtga0ISdiWkxwarolTYtO62uoC7fOIFDJmDqnQYs0HGkpLzD3-wDtXhOW7G6j4857xZuxL4xrG2Rp9eQ52m85Wd-D22SpazK46mWtTpU_1Uf5fMyiA</recordid><startdate>20230223</startdate><enddate>20230223</enddate><creator>GUJJAR, Chaitanya Yogananda</creator><creator>FITZNER, Ansgar</creator><creator>RALLABANDI, Bala Ramesha Chary</creator><creator>SAGILI, Manohar Reddy</creator><creator>MANKALA, Santhosh Kumar</creator><creator>DÖBBER, Alexander</creator><creator>KALAMATA, Venkatasimhadri Naidu</creator><creator>MADALLAPALLI, Kiran Kumar</creator><scope>EVB</scope></search><sort><creationdate>20230223</creationdate><title>PREVENTION OF THE CONVERSION OF PHARMACEUTICAL AGENTS INTO TOXIC N-NITROSAMINE COMPOUNDS</title><author>GUJJAR, Chaitanya Yogananda ; FITZNER, Ansgar ; RALLABANDI, Bala Ramesha Chary ; SAGILI, Manohar Reddy ; MANKALA, Santhosh Kumar ; DÖBBER, Alexander ; KALAMATA, Venkatasimhadri Naidu ; MADALLAPALLI, Kiran Kumar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_US2023056424A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2023</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>GUJJAR, Chaitanya Yogananda</creatorcontrib><creatorcontrib>FITZNER, Ansgar</creatorcontrib><creatorcontrib>RALLABANDI, Bala Ramesha Chary</creatorcontrib><creatorcontrib>SAGILI, Manohar Reddy</creatorcontrib><creatorcontrib>MANKALA, Santhosh Kumar</creatorcontrib><creatorcontrib>DÖBBER, Alexander</creatorcontrib><creatorcontrib>KALAMATA, Venkatasimhadri Naidu</creatorcontrib><creatorcontrib>MADALLAPALLI, Kiran Kumar</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>GUJJAR, Chaitanya Yogananda</au><au>FITZNER, Ansgar</au><au>RALLABANDI, Bala Ramesha Chary</au><au>SAGILI, Manohar Reddy</au><au>MANKALA, Santhosh Kumar</au><au>DÖBBER, Alexander</au><au>KALAMATA, Venkatasimhadri Naidu</au><au>MADALLAPALLI, Kiran Kumar</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>PREVENTION OF THE CONVERSION OF PHARMACEUTICAL AGENTS INTO TOXIC N-NITROSAMINE COMPOUNDS</title><date>2023-02-23</date><risdate>2023</risdate><abstract>A pharmaceutical composition, which is an oral solid dosage form, containing a pharmaceutical agent comprising a dialkylamino- or a trialkylamino-group and one or more pharmaceutically acceptable excipient(s),wherein over a period of2 weeks at 60° C. under open exposure (at any humidity between 30 and 75% rH), or6 months at 40° C./75% rH in the primary packaging, or6 months at 25° C./60% rH in the primary packagingthe concentration of the corresponding N-nitroso-derivative of the pharmaceutical agent remains below 50 ppm (relative to the weight of the free base of the pharmaceutical agent in the pharmaceutical composition).</abstract><oa>free_for_read</oa></addata></record>
fulltext	fulltext_linktorsrc
identifier
ispartof
issn
language	eng
recordid	cdi_epo_espacenet_US2023056424A1
source	esp@cenet
subjects	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
title	PREVENTION OF THE CONVERSION OF PHARMACEUTICAL AGENTS INTO TOXIC N-NITROSAMINE COMPOUNDS
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T09%3A23%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=GUJJAR,%20Chaitanya%20Yogananda&rft.date=2023-02-23&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EUS2023056424A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true